Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 03, 2025 09:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Present New Mitapivat Data in Rare Blood Disorders at 67th ASH Annual Meeting and Exposition

Agios today announced that new data on mitapivat, an oral pyruvate kinase activator, will be featured in oral and poster presentations during ASH
October 30, 2025 06:30 ET | Source: Agios Pharmaceuticals, Inc.

Agios Reports Third Quarter 2025 Financial Results and Provides Business Update

Agios today announced financial results and updates for the third quarter ended September 30, 2025.
October 17, 2025 08:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios’ PYRUKYND® (mitapivat) Receives Positive CHMP Opinion for Adults with Thalassemia

Agios today announced that the CHMP has adopted a positive opinion for the new indication for PYRUKYND in adults for anemia associated with thalassemia
October 16, 2025 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios to Host Third Quarter 2025 Financial Results Conference Call and Webcast on October 30 at 8:00 a.m. ET

Agios today announced the company will host a conference call and live webcast on Thursday, October 30, 2025, at 8:00 a.m. ET to report its third quarter
September 04, 2025 07:00 ET | Source: Agios Pharmaceuticals, Inc.

Agios Provides Update on U.S. PDUFA Goal Date for PYRUKYND® (mitapivat) in Thalassemia

Agios announced that the U.S. FDA has extended the PDUFA goal date for the sNDA of PYRUKYND for adults with thalassemia by three months to December 7, 2025
August 04, 2025 16:01 ET | Source: Agios Pharmaceuticals, Inc.

Agios’ PYRUKYND® (mitapivat) Approved for Adults with Thalassemia in Saudi Arabia

Agios Pharmaceuticals today announced that the Saudi Food and Drug Authority has approved PYRUKYND® for the treatment of adult patients with thalassemia